Keyphrases
Catenin
100%
Abacavir
100%
Osteoblast Lineage Cells
100%
Anti-HIV Drugs
100%
Antiretroviral
72%
Dolutegravir
63%
Tenofovir Disoproxil Fumarate
45%
Combined Antiretroviral Therapy (cART)
27%
Bone Mineral Density
18%
Bone Formation
18%
Bone Marrow
18%
Circulating Levels
18%
Structural Change
9%
Anabolic Effect
9%
Hypo
9%
In Vitro Activity
9%
Target Gene Expression
9%
Bone Turnover Markers
9%
People Living with HIV (PLHIV)
9%
C57BL
9%
Osteoblastic
9%
Primary Osteoblasts
9%
Procollagen Type 1 N-terminal Propeptide (P1NP)
9%
Cortical Areas
9%
Femur
9%
Lamivudine
9%
Osteocyte
9%
Vertebrae
9%
Bone Tissue
9%
Human Males
9%
Lumbar Bone Mineral Density
9%
Cortical Thickness
9%
Bone Mineral Density Loss
9%
Osteogenic Activity
9%
LEF1
9%
Connectivity Rate
9%
Enriched Samples
9%
TOPflash
9%
Medicine and Dentistry
Catenin
100%
Osteoblast
100%
Anti-Human Immunodeficiency Virus
100%
Abacavir
100%
Dolutegravir
60%
Tenofovir Disoproxil
50%
Bone Density
40%
Antiretroviral Therapy
30%
Ossification
30%
Lamivudine
30%
In Vitro
20%
Gene Expression
10%
Human Immunodeficiency Virus
10%
C57BL/6
10%
Lumbar Spine
10%
Skeleton
10%
Osteocyte
10%
Bone Tissue
10%
Vertebra
10%
Connectivity Density
10%
Abacavir Plus Dolutegravir Plus Lamivudine
10%
Biochemistry, Genetics and Molecular Biology
Human Immunodeficiency Virus
100%
Catenin
100%
Osteoblast
100%
Abacavir
100%
Tenofovir
45%
Bone Density
36%
Lamivudine
36%
Ossification
27%
Gene Expression
9%
C57BL 6 Mouse
9%
Osteocyte
9%
Connectivity Density
9%
Pharmacology, Toxicology and Pharmaceutical Science
Anti-Human Immunodeficiency Virus
100%
Catenin
100%
Abacavir
100%
Dolutegravir
60%
Tenofovir Disoproxil
50%
Lamivudine
30%
HIV
10%
C57BL 6 Mouse
10%
Abacavir Plus Dolutegravir Plus Lamivudine
10%